Condition
Secondary Hyperoxaluria
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (2)
P 3 (1)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03346369Phase 3CompletedPrimary
Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis
NCT03095885Not ApplicableCompletedPrimary
A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria
NCT02503345Phase 2CompletedPrimary
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones
NCT02547805Phase 2CompletedPrimary
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days
Showing all 4 trials